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Abstract
Background
Patient-reported disease perceptions are important components to be considered within a
holistic model of quality of care. Gender may have an influence on these perceptions. We
aimed to explore gender-specific concerns of patients included in a national bilingual inflam-
matory bowel disease cohort.
Methods
Following a qualitative study, we built a questionnaire comprising 37 items of concern.
Answers were collected on a visual analog scale ranging from 0 to 100. Principal axis factor
analysis was used to explore concern domains. Linear multiple regressions were conducted
to assess associations with patient characteristics.
Results
Of 1102 patients who replied to the survey, 54% were female and 54% had Crohn’s disease.
We identified six domains of concern: socialization and stigmatization, disease-related con-
straints and uncertainty, symptoms and their impact on body and mind, loss of body control
(including sexuality), disease transmission, and long-term impact of the disease. Cancer
concerns were among the highest scored by all patients (median 61.8). Severity of symp-
toms was the only factor associated with concerns, unrelated to dimension and gender
(p<0.015). In women, being >40 years decreased disease-related constraints and uncer-
tainty concerns, and being at home or unemployed increased them. Treatments were asso-
ciated with increased socialization and stigmatization and with increased disease-related
constraints and uncertainty concerns in men. Overall, psychosomatic characteristics were
highly associated with concerns for both men and women. Depending on the concern
dimensions, increased levels of concern were associated with the highest signs of anxiety
in women or depression in men, as well as lower health-related quality of life in men.
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Conclusions
Patients have numerous concerns related to their illness that need to be reassessed regu-
larly. Concerns differ between men and women, suggesting that information and communi-
cation about the disease should take gender differences and subjective perceptions of
quality of life into consideration.
Introduction
Patient-reported perceptions of quality of life (QoL) are important components to consider
because of their potential influence on disease self-management and thus on health outcomes
[1,2]. Compared with objective clinical assessments, subjective considerations of the impact of
the disease and its treatments are viewed with some skepticism [3] by clinicians, although indi-
vidual well-being might be influenced by, e.g., both symptoms and concerns about potential
symptoms. In addition, positive dimensions of QoL are more easily taken into consideration
than negative dimensions such as worries and concerns regarding the impact of the disease,
although these are of equal importance for assessing a patient’s overall well-being [4]. Indeed,
concerns might reflect how conscious the patient is of the disease, thus indicating areas for
knowledge exchange and communication improvements with clinicians.
Studies on concerns of people with inflammatory bowel disease (IBD) have been conducted
since the early 1990s when the Rating Form of IBD Patient Concerns (RFIPC) questionnaire
[5] was developed and validated among a patient association population [6], the largest survey
conducted until now. The RFIPC was used from 1995 to 2012 to assess concerns of smaller
samples of patients from diverse countries that were generally formed by consecutive enroll-
ment of consenting patients in clinical centers [1,7–16]. However, concerns can evolve over
time. Putative reasons for dynamic changes in concerns include improvements in treatment
strategies and in disease- or treatment-related information given to patients over time. One
study investigated changes in concerns over time [14], but the period between assessments was
too short to measure clear differences. In addition, concerns can differ by gender, as women
may perceive symptoms differently than men, due to, e.g., menstrual cycles[17,18], and express
specific coping strategies and perspectives toward living with IBD[19] that may have an impact
on diet[20,21], communication with physicians[22], socialization, or sexual health[23,24].
The aims of the present study were to explore patients’ current concerns, to survey concerns
of a large number of patients included in a national IBD cohort, and to assess gender-specific
concerns and their associated factors.
Methods
Study design
We undertook a mixed-methods study using an exploratory sequential design. We first
conducted two focus group discussions with 14 IBD patients to explore treatments, disease-
related concerns, and expectations. We followed recommendations[25] stating that these dis-
cussions should involve 6 to 12 participants. Detailed patient selection criteria were previously
described[26]. Focus group discussions were audio-recorded and transcribed for research pur-
poses with the participants’ written consent. Content analyses were performed to explore main
categories of concerns being addressed. This allowed us to list additional concerns beyond
those already used in the RFIPC developed in 1991[5]. Moreover, we grouped four items used
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in the RFIPC by combining pairs of items, in keeping with the way they were expressed by
patients: i.e., “feeling dirty or smelly” and “producing unpleasant odors” was labeled “feeling
dirty or smelly or producing unpleasant odors,” and “attractiveness” and “feelings about my
body” was labeled “attractiveness.” We thus built a 37-item questionnaire to conduct the sur-
vey. Answers to the question, “Because of your condition, how concerned are you with. . .?”
were collected on a visual analog scale ranging from 0 to 100 (0 = not at all, 100 = a great deal).
Cohort data
The questionnaire was sent to all adult patients with active follow-up enrolled in the Swiss IBD
Cohort (SIBDC) by January 2015. To characterize patients, we extracted data from SIBDC
databases. Clinical characteristics were collected by gastroenterologists or trained study nurses
during medical visits.
Statistical analysis
Descriptive analyses that included numbers and percentages were performed to characterize
the study population. The mean and median (interquartile range) were calculated for each
concern, as well as the mean (SD) for the sum score. Missing values were replaced by a score of
50, in accordance with the instructions given to patients: “If you have no opinion or are unde-
cided, please put a cross in the middle of the scale.” Means were added to allow international
comparisons, although all measures were non-normally distributed. We used the Wilcoxon
rank-sum test to test distribution differences of the concerns (statistical significance: p-value
<0.0014, with Bonferroni correction for multiple testing); t-tests were performed to test for
mean differences of the sum scores (statistical significance: p-value <0.05). A factor analysis
using the principal axis factor method was conducted to explore the dimensions of the main
concerns[27] because individual concern measures were non-normally distributed. We re-
tained factors with correlation matrix eigenvalues1. The principal axis factor was first con-
ducted with all of the individual concern items, and then the model was respecified by deleting
one item (“ability to have children”) because of its low communality. Varimax rotation with
the Kaiser normalization method was performed, and we retained factors with loadings0.35
[28]. Cronbach’s alphas were calculated to assess the internal consistency of items in each
dimension. For the first four dimensions (i.e., comprising more than two items), we calculated
a non-weighted sum score of each item. We conducted multiple linear regressions, stratified
by gender, to assess associations between concern dimensions and patient characteristics.
We checked associations between concerns and the following variables: type of diagnosis
(Crohn’s disease, ulcerative colitis, IBD—undetermined), Crohn’s disease location (ileal,
ileocolic, colonic only, upper gastrointestinal) and phenotype (inflammatory, stricturing, pen-
etrating, perianal involvement), ulcerative colitis extension (proctitis, left-sided, pancolitis),
history of extraintestinal manifestations and resection surgery (yes/no), highest treatment line
achieved (no treatment, 5-aminosalicylic acid compounds or steroids, immunomodulators,
biologicals), and disease duration. Patient self-reported characteristics, collected through
paper questionnaires, included the following: gender, age, language of questionnaire comple-
tion (French/German), education level (none or compulsory/secondary education [profes-
sional/general], upper secondary education/tertiary education), working status (employed/in
training/at home or unemployed/retired or annuitant). Finally, we assessed the association
between concerns and other health-related QoL measures. We used the SF-36 questionnaire,
divided into two subscores: the Physical Component Summary and the Mental Component
Summary. The Inflammatory Bowel Disease Questionnaire (IBDQ) comprises 32 items and
was assessed with four subscores (bowel symptoms, systemic symptoms, emotional function,
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and social function). Mood was assessed through the Hospital Anxiety and Depression Scale,
which was divided into two subscales, one assessing depression and the other anxiety; coping
was assessed with the Coping Inventory for Stressful Situations [29].
Concern dimensions were normalized by using power transformations. This implied that
crude multiple linear regression coefficients might be difficult to interpret or compare. For
this reason, results were reported with signs and significance of associations only. To properly
separate the effect of anxiety and depression from the effect of QoL measures, we first con-
ducted a linear regression with QoL measures as dependent variables and anxiety and depres-
sion scores as explanatory variables. The residuals of these regressions, i.e., QoL measures
from which the anxiety and depression shared components were removed, were used in the
multiple linear regressions as explanatory variables. To construct multiple linear regression
models, we performed the following steps: (1) We assessed all covariates in univariate linear
regression models; (2) all covariates with a p-value <0.20 were entered into a multiple linear
regression model; (3) nonsignificant covariates were excluded one by one until all remaining
covariates were statistically significant (p-value <0.05); (4) nonsignificant covariates were
added one by one and kept in the model if they became significant until a final model could be
determined, while we checked for model consistency.
Factor analyses were conducted with SPSS Statistics 23 (IBM Corp., New York, NY, USA).
Descriptive and regression analyses were conducted by using STATA statistical software v.14.1
(STATA Corp., College Station, TX, USA).
Ethics approval
Ethics approval was obtained from the regional Swiss Ethics Committees in which cohort
participants were enrolled (Commission d’e´thique du Canton de Vaud/Protocol no. 33/06).
Ethics approval was obtained to conduct focus groups (Commission d’e´thique du Canton de
Vaud /Protocol no. 185/13).
Results
Newly expressed concerns
Analysis of focus group discussion content yielded 14 additional concerns expressed by
patients. These concerns were related to support given by relatives, having to talk about the
disease with relatives, professional future, diet, having to take life-long treatments, the chronic-
ity of the disease, being addicted to medications, the origins of the disease, fatigue, the influ-
ence of the disease on physical and sports performance, the link between stress and disease,
the difficulty in predicting relapses, the ability of children to develop the same disease, and
medical consultations and exams.
Characteristics of the sample population
Among the 2094 patients who actively participated in follow-up and agreed to regularly receive
self-reported questionnaires, 1123 (54%) replied and 1102 could be used in the study. Women
responded more frequently than did men (54% vs. 46%). Socio-demographic variables were
significantly different between men and women (Table 1). Men were older than women (48.7
vs. 46.5 years, respectively; p = 0.017) and had a higher educational level. Indeed, 44.6% of
men had at least an upper secondary education, compared with 27.3% of women (p<0.001),
and a higher proportion of women than men were at home or unemployed (3.8% vs. 14.8%,
respectively; p<0.001). Overall, clinical characteristics and treatments were similar for men
and women, except for extraintestinal manifestations, a history of which was more frequently
Patient-reported indicators in IBD
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Table 1. Baseline patient characteristics. Values are number and percentages unless otherwise specified.
Variables All (N) Men Women p-value
All 1102 504 (45.7) 598 (54.3)
German speakers 761 365 (72.4) 396 (66.2) 0.027
Age* 47.5 (15.2) 48.7 (15.7) 46.5 (14.7) 0.017
Education level <0.001
None or compulsory 100 37 (7.9) 63 (11.0)
Secondary education (professional) 411 165 (35.0) 246 (43.0)
Secondary education (general) 166 59 (12.5) 107 (18.7)
Upper secondary education 214 123 (26.1) 91 (15.9)
Tertiary education 152 87 (18.5) 65 (11.4)
Working status <0.001
Employed 743 357 (74.8) 386 (68.7)
In training 30 13 (2.7) 17 (3.0)
At home/unemployed 101 18 (3.8) 83 (14.8)
Retired/annuitant 165 89 (18.7) 76 (13.5)
Age at diagnosis* 31.8 (13.8) 33.2 (14.4) 30.6 (13.2) 0.003
Disease duration* 15.7 (10.2) 15.6 (10.3) 15.9 (10.1) 0.518
Diagnosis 0.027
CD 596 256 (50.8) 340 (56.9)
UC 475 228 (45.2) 247 (41.3)
IBDU 31 20(4.0) 11 (1.8)
Disease location (CD) 0.320
Ileal 186 86 (33.6) 100 (29.4)
Colonic 209 93 (36.3) 116 (34.1)
Ileocolonic 168 65 (25.4) 103 (30.3)
Upper GI only 14 7 (2.7) 7 (2.1)
Disease behavior (CD) 0.325
Inflammatory 294 118 (46.1) 176 (51.8)
Stricturing 198 88 (34.4) 110 (32.3)
Penetrating 104 50 (19.5) 54 (15.9)
Disease extension (UC) 0.115
Proctitis 117 48 (19.3) 69 (26.7)
Left-sided colitis 207 113 (45.6) 94 (36.4)
Pancolitis 172 83 (33.5) 89 (34.5)
Perianal disease 235 106 (21.0) 129 (21.6) 0.827
Highest treatment line 0.891
No treatment 14 5 (1.0) 9 (1.5)
5-ASA or steroids 232 105 (20.8) 127 (21.2)
Immunomodulators 340 157 (31.1) 183 (30.6)
Biologicals 516 237 (47.0) 279 (46.7)
History of resection surgery 287 135 (26.8) 152 (25.4) 0.606
History of extraintestinal manifestations 585 238 (47.2) 347 (58.0) <0.001
Signs of anxiety <0.001
None 761 376 (78.2) 385 (65.8)
Mild to severe 305 105 (21.8) 200 (34.2)
Signs of depression 0.663
None 903 410 (85.2) 493 (84.3)
Mild to severe 163 71 (14.8) 92 (15.7)
(Continued )
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found in women than in men (58.0% vs. 47.2%, respectively; p<0.001). About one third of
women presented with signs of anxiety, compared with one fifth of men (p<0.001). Signs of
depression were noticed in one seventh of all responders, with no difference between genders.
General and IBD-specific health-related QoL was lower among women than among men.
Levels of individual concerns
Overall, the five most important concerns were loss of bowel control (median score: 70, inter-
quartile range: 38–92), the risk of developing cancer (69, 44–88), the link between stress and
disease (68, 44–86), the chronicity of the disease (66, 43–85), and fatigue (65, 31–88) (Table 2).
The overall level of concern of patients was 45.3.
Main dimensions of concerns
The principal axis factor yielded six main concern dimensions, which were labeled according
to the item(s) with the strongest factor loading (Table 3), namely: (1) socialization and stigma-
tization, (2) constraints and uncertainty, (3) impact of the disease on body and mind (includ-
ing symptoms), (4) loss of body control (including sexuality), (5) disease transmission, and (6)
long-term impact of the disease. Cronbach’s alpha for the items included in each dimension
varied between 0.71 and 0.89. All dimensions explained 48.4% of the common variance. Two
items (“ability to have children” and “medical consultations and exams”) had factors loadings
that were too low and therefore could not be associated with any dimension.
Specific gender-related concerns
When we compared the unadjusted median of specific concerns in the four main dimensions
to identify where the differences might be, we observed that women felt significantly more
concerned by symptoms such as fatigue, pain, and the influence of stress on disease activity
and energy level (Fig 1). Significant gender-related differences were observed for personal con-
cerns such as intimacy (Fig 2) and disease-related disabilities, including loss of bowel control,
feeling out of control, or being unable to predict relapses (Fig 3). Finally, women seemed more
concerned by the burden related to medical consultations and exams, as well as by the social
impact of living with the disease. Constraints and uncertainty concerns were not gender spe-
cific (Fig 4). Women had significantly higher overall levels of concern than did men (sum
score: 47.5 vs. 42.8, respectively, p<0.001)
Factors associated with concerns
Symptom severity was the only factor associated with increased concerns, regardless of the
dimension (Table 4). Education level and disease location or phenotypic characteristics
were not associated with any concern dimension. Overall, factors associated with concern
Table 1. (Continued)
Variables All (N) Men Women p-value
SF36 physical component* 49.4 (9.2) 51.0 (8.1) 48.2 (9.9) <0.001
SF36 mental component* 46.6 (10.6) 48.3 (9.7) 45.1 (11.1) <0.001
IBDQ sum score* 57.7 (9.8) 59.7 (8.8) 56.1 (10.2) <0.001
* Mean (SD).
CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease—undetermined; GI, gastrointestinal; 5-ASA, 5-aminosalicylic acid; IBDQ,
Inflammatory Bowel Disease Questionnaire.
doi:10.1371/journal.pone.0171864.t001
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dimensions differed according to gender and dimension. Socio-demographic characteristics
had an effect on the level of some concerns for women and disease-related characteristics for
men. Overall, psychosomatic characteristics were highly associated with concerns of both men
and women. Increased levels of concern were associated with the highest signs of anxiety or
depression and with lower health-related QoL.
Women living in the French-speaking region of Switzerland had fewer concerns about
symptoms or disease-related constraints and uncertainty than did those in the German-speak-
ing region. Moreover, women at home or unemployed had higher concerns about disease-
Table 2. Mean, median, and interquartile range (IQR) scores for each concern according to gender,
type of diagnosis, language, and age.
Dimension Mean Median (IQR)
Loss of bowel control 61.8 70 (38–92)
Developing cancer 61.1 69 (44–88)
Link between stress and disease 60.3 68 (44–86)
Chronicity of the disease 60.1 66 (43–85)
Fatigue 58.5 65 (31–88)
Having to take life-long treatments 55.8 64 (23–87)
Uncertain nature of the disease 57.7 63 (34–85)
Treatment side effects 54.5 63 (20–84)
Difficulty in predicting relapses 54.6 58 (28–82)
Ability of children to develop the same disease 55.7 58 (25–88)
Having surgery 54.2 57 (20–86)
Energy level 53.1 56.5 (21–79)
Having an ostomy bag 51.9 52 (14–87)
Being addicted to medications 49.5 52 (14–81)
Pain 49.3 51 (19–76)
Influence of the disease on physical and sports performance 47.7 51 (15–74)
Origins of the disease 47.4 51 (13–76)
Ability to achieve full potential 45.3 49 (12–71)
Feeling out of control 43.8 47 (8–75)
Impact on sexual life 43.6 47 (10–70)
Loss of sexual drive 40.3 44 (6–67)
Diet 41.5 43.5 (9–68)
Medical consultations and exams 40.7 41 (11–67)
Intimacy 38.7 37.5 (7–62)
Dying early 39.4 35 (8–65)
Support by relatives 36.1 34 (6–54)
Being a burden on others 39.2 32 (6–69)
Professional future 36.9 29 (6–62)
Having access to quality medical care 37.7 28 (7–66)
Attractiveness 35.9 28 (5–62)
Feeling alone 33.0 19.5 (5–54)
Feeling "dirty" or "smelly" or producing unpleasant odors 34.1 19 (4–62)
Financial difficulties 30.4 16 (4–52)
Ability to have children 30.3 15 (3–50)
Being treated as different 27.1 14 (4–49)
Having to talk about disease with relatives 27.3 14 (4–49)
Passing disease on to others 32.9 14 (3–57)
Sum score 45.3
doi:10.1371/journal.pone.0171864.t002
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Table 3. Results of the rotated factor matrix.
Dimensions
Concerns Socialization and
stigmatization
Constraints and
uncertainty
Symptoms (impact
on body and mind)
Loss of body control
(including sexuality)
Disease
transmission
Long-term
impact
Feeling alone 0.64 0.10 0.25 0.18 0.07 0.20
Being treated as different 0.63 0.11 0.14 0.23 0.07 0.19
Intimacy 0.58 0.14 0.25 (0.39) 0.16 0.11
Support by relatives 0.52 0.16 0.26 0.15 0.10 0.11
Being a burden on others 0.51 0.19 0.33 0.28 0.12 0.01
Professional future 0.50 0.23 (0.37) 0.12 0.01 0.06
Financial difficulties 0.50 0.22 0.27 0.05 0.04 0.02
Having access to quality
medical care
0.49 0.23 0.12 0.08 0.16 0.18
Having to talk about disease
with relatives
0.49 0.21 0.03 0.12 -0.05 0.01
Feeling "dirty" or "smelly" or
producing unpleasant odors
0.48 0.02 0.12 (0.45) 0.13 0.14
Attractiveness 0.42 0.20 0.31 0.24 0.21 0.04
Diet 0.35 0.32 0.26 0.19 0.08 0.00
Having to take life-long
treatments
0.18 0.70 0.09 0.09 0.09 0.09
Chronicity of the disease 0.16 0.65 0.19 0.27 0.03 0.07
Treatment side effects 0.14 0.57 0.19 0.02 0.04 0.11
Uncertain nature of the
disease
0.17 0.56 0.17 0.32 0.13 0.27
Being addicted to
medications
0.15 0.55 0.13 0.07 0.13 0.19
Origins of the disease 0.19 0.38 0.12 0.12 0.19 0.30
Energy level 0.25 0.17 0.73 0.25 0.10 0.13
Fatigue 0.25 0.28 0.63 0.19 0.14 0.05
Ability to achieve full
potential
(0.36) 0.21 0.62 0.13 0.04 0.23
Influence of the disease on
physical and sports
performance
0.30 0.22 0.50 0.24 0.10 0.10
Pain 0.34 (0.36) 0.37 0.21 0.14 0.02
Link between stress and
disease
0.23 0.33 0.35 0.15 0.12 0.17
Loss of bowel control 0.21 0.30 0.24 0.59 0.14 0.10
Feeling out of control (0.43) 0.14 0.19 0.53 0.13 0.16
Impact on sexual life (0.39) 0.17 0.33 0.52 0.11 -0.04
Difficulty in predicting
relapses
0.21 (0.47) 0.28 0.47 0.14 0.11
Loss of sexual drive (0.35) 0.07 0.32 0.45 0.15 0.12
Having surgery 0.20 (0.40) 0.11 0.44 0.12 0.26
Having an ostomy bag 0.16 0.17 0.14 0.43 0.18 0.31
Passing disease on to others 0.16 0.10 0.09 0.14 0.79 0.18
Ability of children to develop
the same disease
0.06 0.22 0.14 0.20 0.59 0.12
Developing cancer 0.08 (0.38) 0.10 0.24 0.14 0.58
Dying early 0.22 0.26 0.14 0.10 0.11 0.55
(Continued )
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related constraints and uncertainty (p = 0.004). Socio-demographic characteristics did not
have much effect on the level of concerns among men. French-speaking men had increased
concerns about loss of body control than did German-speaking men (p = 0.042).
The burden linked to treatment was associated with concerns only for men. More specifi-
cally, socialization and stigmatization concerns significantly increased for men receiving
immunomodulators (p = 0.020) or biologicals (p = 0.07); the same was observed for disease-
related constraints and uncertainty (p = 0.024 and p = 0.009, respectively). A history of resec-
tion surgery was associated with lower concerns related to constraints and uncertainty among
men (p = 0.001) and with higher socialization and stigmatization concerns among women
(p = 0.026). The level of concern about symptoms was higher in women with a history of extra-
intestinal manifestations.
Increased levels of concern of any type were associated with signs of anxiety (p0.005) and
higher emotional coping (p0.015) among women. Women’s concerns that were related to
socialization and stigmatization and to loss of body control decreased with a better IBDQ
social subscore and SF-36 Physical Component Summary score. Men’s concerns about sociali-
zation and stigmatization and about symptoms increased with signs of anxiety, although the
significance of the association was not as high as that observed among women and was not
present regardless of the level of anxiety. Increased concerns of men linked to socialization
and stigmatization and to loss of body control were associated with signs of depression. Signs
of depression were never associated with higher concerns in women. Symptom concerns
decreased with better general QoL and with higher IBDQ bowel symptoms in men. Psychoso-
matic characteristics were not associated with concerns linked to symptoms among men.
Table 3. (Continued)
Dimensions
Concerns Socialization and
stigmatization
Constraints and
uncertainty
Symptoms (impact
on body and mind)
Loss of body control
(including sexuality)
Disease
transmission
Long-term
impact
Medical consultations and
exams
0.31 0.34 0.11 0.07 0.09 0.08
Ability to have children - - - - - -
% of total variance
explained
12.9 10.6 8.8 8.2 4.0 3.9
Cronbach’s alpha 0.89 0.82 0.85 0.86 0.72 0.71
doi:10.1371/journal.pone.0171864.t003
Fig 1. Median for individual concerns related to symptoms according to gender.
doi:10.1371/journal.pone.0171864.g001
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Discussion
This study aimed at assessing current and gender-specific concerns related to disease and
treatments among IBD patients included in a national cohort study. Five of the 14 additional
concerns we evaluated were among the top 10 scored by patients. Women in general had more
concerns than did men. We found that signs of anxiety were highly associated with concerns,
especially for women, and signs of depression were associated with only some types of con-
cerns among men. General SF-36 and IBD-specific QoL measures were related to concerns
related to symptoms. The burden linked to treatments only was associated with increased con-
cerns among men. Symptom severity was the only factor highly associated with any type of
concern and was unrelated to gender.
Our study was performed on 1102 patients included in a national cohort, which corre-
sponds to the largest sample of patients screened for concerns at a country level.
We found that concern items traditionally used, based on the study conducted 25 years ago
[5], have changed over time. Indeed, a set of new concerns were first expressed by patients dur-
ing the qualitative study. Second, our cross-sectional survey showed that, when considering
the whole sets of concerns, some of the old ones were rated much differently as observed in
1991 and 11 of the 14 new ones had a mean/median rating score> 40.
Fig 2. Median for individual concerns related to socialization and stigmatization according to gender.
doi:10.1371/journal.pone.0171864.g002
Fig 3. Median for individual concerns related to loss of body control according to gender.
doi:10.1371/journal.pone.0171864.g003
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We observed that the mean rating scores of the most important concerns were higher than
those measured in previous studies. This might indicate that IBD patients today have an
increased consciousness about their disease and increased responsibility towards it. This posi-
tive aspect might also indicate an increased willingness to exchange and communicate about
the disease. In comparison with previous studies, our study outlined different main concerns
than those previously found. In our cohort, loss of bowel control and developing cancer were
the highest concerns ranked by patients, in contrast to previously identified main concerns,
i.e., ostomy bag, medication side effects[8,11,13,16], or uncertainty about the nature of the dis-
ease[13,16]. The concern about loss of bowel control had markedly increased between the
1990s [8] to 2000s (44.2–47.5)[11,13,16] and today (mean rating of 37.8 to 61.8). This might
reflect the global burden of the disease and a change of attitude in patients, in that it seems eas-
ier to talk about IBD today than it was in the past. Such a mean score increase has also been
observed for concerns linked to cancer (from 38.0[8] to 61.1). Increased patient information
about their risk of cancer might explain why this concern scored higher than it did in previous
studies[30]. It could also be due to increased penetrance of colon surveillance for cancer by
repeated endoscopies. The effects of medications, of having an ostomy bag, and of the uncer-
tain nature of the disease were still important concerns, as noted in previous studies. We also
observed that six of the additional concerns we added were highly rated (mean rating scores
above 55), even higher than any concerns explored in previous studies. Among those highly
rated concerns, two were associated with symptoms: the link between stress and disease, and
fatigue. Fatigue was shown to be associated with concerns in patients with IBD [31], and our
study tends to further indicate that fatigue is not only associated with concerns and worries,
but is a concern itself, especially for women. Patients included in the SIBDC mainly speak two
national languages, German and French, as inclusions have not yet started in the Italian-speak-
ing part of Switzerland. This is thus the first study in which a comparison of regional cultural
aspects between two groups of patients evolving in the same healthcare system is possible,
compared with the study of Levenstein et al.[13]. In our study, we found that some concerns
were higher or lower according to language, with differences being observed in men and
women.
Overall, we found that independent factors associated with concerns highly varied with
gender, regardless of the factor, except symptom severity, which confirmed previous tenden-
cies[15]. Symptom frequency was not associated with concerns. Socio-demographic variables
were associated with constraints and uncertainty concerns, as previously found [11], but we
Fig 4. Median for individual concerns related to constraints and uncertainty according to gender.
doi:10.1371/journal.pone.0171864.g004
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confirmed this association only among women. Interestingly, the burden linked to treatments
was associated with stigmatization and constraint concerns only among men, with men who
Table 4. Multiple linear regressions for each concern dimension stratified by gender. Values indicate the direction of the association and the p-value.
Socialization and
stigmatization
Constraints and
uncertainty
Symptoms (impact on
body and mind)
Loss of body control
(including sexuality)
Men Women Men Women Men Women Men Women
Socio-demographic characteristics
Age >40 years - / 0.014
French speakers - / 0.023 - / <0.001 + / 0.042
Occupation
Employed ref
In training - / 0.230
At home/unemployed + / 0.004
Resident/annuitant + / 0.867
Disease-related characteristics
Disease duration
0–5 years ref
5–15 years - / 0.137
>15 years - / 0.015
Symptom severity + / <0.001 + / <0.001 + / <0.001 + / 0.014 + / <0.001 + / <0.001 + / <0.001 + / 0.001
Highest treatment line
No treatment ref ref ref
5-ASA/steroids + / 0.042 + / 0.075 + / 0.268
Immunomodulators + / 0.020 + / 0.024 + / 0.189
Biologicals + / 0.007 + / 0.009 + / 0.078
History of resection surgery + / 0.026 - / 0.001
History of extraintestinal manifestations + / 0.014
Psychosomatic characteristics
Signs of anxiety
None ref ref ref ref ref ref
Mild + / 0.039 + / <0.001 + / 0.005 + / 0.261 + / 0.001 + / 0.001
Moderate + / 0.061 + / <0.001 + / 0.005 + / 0.007 + / <0.001 + / <0.001
Severe + / 0.047 + / <0.001 + / <0.001 + / 0.018 + / <0.001 + / <0.001
Signs of depression
None ref ref
Mild + / 0.001 + / <0.001
Moderate + / 0.104 + / 0.007
Severe + / 0.441 + / 0.543
SF-36 MCS* - / 0.043
SF-36 PCS* - / 0.003 - / <0.001
IBDQ bowel* subscore + / 0.035
IBDQ social* subscore - / 0.015 - / <0.001
Task coping + / 0.002
Emotional coping + / 0.025 + / 0.005 + / 0.006 + / 0.013 + / <0.001 + / 0.015
Avoidance coping - / 0.031
* Component unrelated to anxiety and depression.
5-ASA, 5-aminosalicylic acid; MCS, Mental Component Summary; PCS, Physical Component Summary; IBDQ, Inflammatory Bowel Disease
Questionnaire.
doi:10.1371/journal.pone.0171864.t004
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were receiving biologicals being the most concerned about these issues. This might be partly
explained because the highest proportion of men were employed, and thus men had more
implicit difficulties in combining constraints linked to treatments and work. On the other
hand–and because occupation status was not explicitly associated with these types of concerns
in men–this might also indicate that men may have more difficulties in accepting, and thus
sharing, disease-related disabilities at work or in other social groups. This might add to previ-
ous gender difference observations about crude but not adjusted group comparisons[12]. His-
tory of previous resection increased stigma concerns among women, but lowered constraint
concerns among men, a more specific result than was previously found[9]. Another important
finding was the association of concerns with psychosomatic measures, high differences
depending on gender. In women, the greater the concerns, the higher were the signs of anxiety,
regardless of the type of concern. Greater concerns related to socialization and stigmatization
and loss of body control were associated with signs of depression in men, but not in women.
This is in line with previous observations that men may be more emotionally affected than
women when the disease is more complex and in the presence of associated complications
[32]. Concerns about symptoms had a more important effect on men’s QoL than on that of
women, as measured by standard general and disease-specific indicators. Two hypothesizes
can be drawn; namely, the perception of QoL may be gender specific or symptoms may be per-
ceived differently according to gender. A study by Hauser et al.[33] showed that women, after
controlling for disease characteristics, had lower health-related QoL scores than did men. This
may indicate that concerns related to symptoms may be able to better discriminate QoL mea-
sures in men, but not in women. Previous observations from qualitative studies indeed showed
that women expressed a significantly lower level of general health-related QoL and more emo-
tional disturbances related to their disease, as well as more frequent bowel symptoms com-
pared with those of men[33]. Women seemed also to perceive a more negative impact and
effects of IBD compared with those of men[33,34].
The main strength of our study was related to the large sample size of IBD patients that
could be surveyed. Moreover, all of them could be deeply characterized because of the data
that were collected through cohort enrollment and follow-up questionnaires. This comprised
data from medical visits and from patient self-reported questionnaires, especially psychometric
measures. In our study, we could investigate patients’ concerns at a country level. The fact that
patients were followed in university centers or in private practices might help to minimize the
potential selection bias, although our study is not population-based. One limitation was related
to the survey’s response rate, which may lead to a nonresponse bias, although the impact on
the results, in terms of potentially different distributions of concern ratings among nonre-
sponders, is impossible to estimate. We could probably have slightly increased this rate by
sending a reminder to patients, but the time available to conduct the study was limited and we
decided not to bother patients too much by sending them questionnaires again in a short time
frame. This also corresponds to the reality of long-term observational studies, with patients
regularly invited to contribute to data collection[35], which may drive attrition.
In conclusion, worries and concerns of patients need to be considered when discussing per-
spectives about good quality of care. IBD is a high-burden disease, and patients seem to have
important gender-specific [36] concerns related to their illness that need to be reassessed regu-
larly, taking into account advances in healthcare over time.
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